Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
60
LIVN Quote, Financials, Valuation and Earnings
Last price:
$63.66
Seasonality move
:
9.24%
Day range:
$62.56 - $64.18
52-week range:
$32.48 - $64.31
Dividend yield:
0%
P/E ratio:
38.16x
P/S ratio:
2.59x
P/B ratio:
3.02x
Volume:
496K
Avg. volume:
643.4K
1-year change:
24.83%
Market cap:
$3.5B
Revenue:
$1.3B
EPS (TTM):
-$4.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LIVN
LivaNova Plc
|
$342.3M | $0.92 | 9.86% | -20.69% | $69.10 |
|
ABT
Abbott Laboratories
|
$11.4B | $1.30 | 7.5% | -71.7% | $144.43 |
|
CATX
Perspective Therapeutics, Inc.
|
$206.8K | -$0.32 | -9.65% | -37.91% | $12.3077 |
|
NVCR
NovoCure Ltd.
|
$158.9M | -$0.42 | 4.75% | -35.35% | $24.93 |
|
TCMD
Tactile Systems Technology, Inc.
|
$79.3M | $0.21 | 9.6% | 12.09% | $18.83 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$32.7M | -- | 2.34% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LIVN
LivaNova Plc
|
$63.90 | $69.10 | $3.5B | 38.16x | $0.00 | 0% | 2.59x |
|
ABT
Abbott Laboratories
|
$125.40 | $144.43 | $218.1B | 15.73x | $0.59 | 1.88% | 5.00x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.3900 | $12.3077 | $177.7M | -- | $0.00 | 0% | 162.05x |
|
NVCR
NovoCure Ltd.
|
$11.76 | $24.93 | $1.3B | -- | $0.00 | 0% | 2.02x |
|
TCMD
Tactile Systems Technology, Inc.
|
$26.81 | $18.83 | $598.8M | 34.61x | $0.00 | 0% | 2.02x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.61 | $1.50 | $85.4M | 59.83x | $0.00 | 0% | 0.67x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LIVN
LivaNova Plc
|
29.6% | 1.882 | 17.01% | 1.05x |
|
ABT
Abbott Laboratories
|
20.25% | 0.426 | 5.99% | 1.12x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
NVCR
NovoCure Ltd.
|
70.04% | -1.015 | 55.15% | 1.44x |
|
TCMD
Tactile Systems Technology, Inc.
|
7.55% | -0.272 | 5.41% | 2.63x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 2.955 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LIVN
LivaNova Plc
|
$244.9M | $56.6M | -12.15% | -18.29% | 15.83% | $62.2M |
|
ABT
Abbott Laboratories
|
$5.9B | $2.2B | 22.49% | 29.06% | 19.03% | $2.3B |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
NVCR
NovoCure Ltd.
|
$122.5M | -$36M | -16.67% | -50.08% | -21.54% | $14.9M |
|
TCMD
Tactile Systems Technology, Inc.
|
$64.4M | $11M | 7.42% | 8.82% | 12.78% | $9.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
LivaNova Plc vs. Competitors
-
Which has Higher Returns LIVN or ABT?
Abbott Laboratories has a net margin of 7.49% compared to LivaNova Plc's net margin of 14.07%. LivaNova Plc's return on equity of -18.29% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital LIVNLivaNova Plc68.44% $0.49 $1.6B ABTAbbott Laboratories52.05% $0.91 $64.2B -
What do Analysts Say About LIVN or ABT?
LivaNova Plc has a consensus price target of $69.10, signalling upside risk potential of 8.14%. On the other hand Abbott Laboratories has an analysts' consensus of $144.43 which suggests that it could grow by 15.18%. Given that Abbott Laboratories has higher upside potential than LivaNova Plc, analysts believe Abbott Laboratories is more attractive than LivaNova Plc.
Company Buy Ratings Hold Ratings Sell Ratings LIVNLivaNova Plc5 2 0 ABTAbbott Laboratories15 7 0 -
Is LIVN or ABT More Risky?
LivaNova Plc has a beta of 1.020, which suggesting that the stock is 2.023% more volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.716, suggesting its less volatile than the S&P 500 by 28.412%.
-
Which is a Better Dividend Stock LIVN or ABT?
LivaNova Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.88% to investors and pays a quarterly dividend of $0.59 per share. LivaNova Plc pays -- of its earnings as a dividend. Abbott Laboratories pays out 29.33% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LIVN or ABT?
LivaNova Plc quarterly revenues are $357.8M, which are smaller than Abbott Laboratories quarterly revenues of $11.4B. LivaNova Plc's net income of $26.8M is lower than Abbott Laboratories's net income of $1.6B. Notably, LivaNova Plc's price-to-earnings ratio is 38.16x while Abbott Laboratories's PE ratio is 15.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LivaNova Plc is 2.59x versus 5.00x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIVNLivaNova Plc2.59x 38.16x $357.8M $26.8M ABTAbbott Laboratories5.00x 15.73x $11.4B $1.6B
-
Which has Higher Returns LIVN or CATX?
Perspective Therapeutics, Inc. has a net margin of 7.49% compared to LivaNova Plc's net margin of -12425.36%. LivaNova Plc's return on equity of -18.29% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital LIVNLivaNova Plc68.44% $0.49 $1.6B CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About LIVN or CATX?
LivaNova Plc has a consensus price target of $69.10, signalling upside risk potential of 8.14%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 414.97%. Given that Perspective Therapeutics, Inc. has higher upside potential than LivaNova Plc, analysts believe Perspective Therapeutics, Inc. is more attractive than LivaNova Plc.
Company Buy Ratings Hold Ratings Sell Ratings LIVNLivaNova Plc5 2 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is LIVN or CATX More Risky?
LivaNova Plc has a beta of 1.020, which suggesting that the stock is 2.023% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock LIVN or CATX?
LivaNova Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LivaNova Plc pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LIVN or CATX?
LivaNova Plc quarterly revenues are $357.8M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. LivaNova Plc's net income of $26.8M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, LivaNova Plc's price-to-earnings ratio is 38.16x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LivaNova Plc is 2.59x versus 162.05x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIVNLivaNova Plc2.59x 38.16x $357.8M $26.8M CATXPerspective Therapeutics, Inc.162.05x -- $209K -$26M
-
Which has Higher Returns LIVN or NVCR?
NovoCure Ltd. has a net margin of 7.49% compared to LivaNova Plc's net margin of -22.29%. LivaNova Plc's return on equity of -18.29% beat NovoCure Ltd.'s return on equity of -50.08%.
Company Gross Margin Earnings Per Share Invested Capital LIVNLivaNova Plc68.44% $0.49 $1.6B NVCRNovoCure Ltd.73.25% -$0.33 $1.1B -
What do Analysts Say About LIVN or NVCR?
LivaNova Plc has a consensus price target of $69.10, signalling upside risk potential of 8.14%. On the other hand NovoCure Ltd. has an analysts' consensus of $24.93 which suggests that it could grow by 111.98%. Given that NovoCure Ltd. has higher upside potential than LivaNova Plc, analysts believe NovoCure Ltd. is more attractive than LivaNova Plc.
Company Buy Ratings Hold Ratings Sell Ratings LIVNLivaNova Plc5 2 0 NVCRNovoCure Ltd.4 2 0 -
Is LIVN or NVCR More Risky?
LivaNova Plc has a beta of 1.020, which suggesting that the stock is 2.023% more volatile than S&P 500. In comparison NovoCure Ltd. has a beta of 0.825, suggesting its less volatile than the S&P 500 by 17.463%.
-
Which is a Better Dividend Stock LIVN or NVCR?
LivaNova Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovoCure Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LivaNova Plc pays -- of its earnings as a dividend. NovoCure Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LIVN or NVCR?
LivaNova Plc quarterly revenues are $357.8M, which are larger than NovoCure Ltd. quarterly revenues of $167.2M. LivaNova Plc's net income of $26.8M is higher than NovoCure Ltd.'s net income of -$37.3M. Notably, LivaNova Plc's price-to-earnings ratio is 38.16x while NovoCure Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LivaNova Plc is 2.59x versus 2.02x for NovoCure Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIVNLivaNova Plc2.59x 38.16x $357.8M $26.8M NVCRNovoCure Ltd.2.02x -- $167.2M -$37.3M
-
Which has Higher Returns LIVN or TCMD?
Tactile Systems Technology, Inc. has a net margin of 7.49% compared to LivaNova Plc's net margin of 9.57%. LivaNova Plc's return on equity of -18.29% beat Tactile Systems Technology, Inc.'s return on equity of 8.82%.
Company Gross Margin Earnings Per Share Invested Capital LIVNLivaNova Plc68.44% $0.49 $1.6B TCMDTactile Systems Technology, Inc.75.1% $0.36 $221.7M -
What do Analysts Say About LIVN or TCMD?
LivaNova Plc has a consensus price target of $69.10, signalling upside risk potential of 8.14%. On the other hand Tactile Systems Technology, Inc. has an analysts' consensus of $18.83 which suggests that it could fall by -10.48%. Given that LivaNova Plc has higher upside potential than Tactile Systems Technology, Inc., analysts believe LivaNova Plc is more attractive than Tactile Systems Technology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LIVNLivaNova Plc5 2 0 TCMDTactile Systems Technology, Inc.2 3 0 -
Is LIVN or TCMD More Risky?
LivaNova Plc has a beta of 1.020, which suggesting that the stock is 2.023% more volatile than S&P 500. In comparison Tactile Systems Technology, Inc. has a beta of 0.931, suggesting its less volatile than the S&P 500 by 6.902%.
-
Which is a Better Dividend Stock LIVN or TCMD?
LivaNova Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tactile Systems Technology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LivaNova Plc pays -- of its earnings as a dividend. Tactile Systems Technology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LIVN or TCMD?
LivaNova Plc quarterly revenues are $357.8M, which are larger than Tactile Systems Technology, Inc. quarterly revenues of $85.8M. LivaNova Plc's net income of $26.8M is higher than Tactile Systems Technology, Inc.'s net income of $8.2M. Notably, LivaNova Plc's price-to-earnings ratio is 38.16x while Tactile Systems Technology, Inc.'s PE ratio is 34.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LivaNova Plc is 2.59x versus 2.02x for Tactile Systems Technology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIVNLivaNova Plc2.59x 38.16x $357.8M $26.8M TCMDTactile Systems Technology, Inc.2.02x 34.61x $85.8M $8.2M
-
Which has Higher Returns LIVN or XTNT?
Xtant Medical Holdings, Inc. has a net margin of 7.49% compared to LivaNova Plc's net margin of 3.93%. LivaNova Plc's return on equity of -18.29% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital LIVNLivaNova Plc68.44% $0.49 $1.6B XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About LIVN or XTNT?
LivaNova Plc has a consensus price target of $69.10, signalling upside risk potential of 8.14%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 145.78%. Given that Xtant Medical Holdings, Inc. has higher upside potential than LivaNova Plc, analysts believe Xtant Medical Holdings, Inc. is more attractive than LivaNova Plc.
Company Buy Ratings Hold Ratings Sell Ratings LIVNLivaNova Plc5 2 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is LIVN or XTNT More Risky?
LivaNova Plc has a beta of 1.020, which suggesting that the stock is 2.023% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.
-
Which is a Better Dividend Stock LIVN or XTNT?
LivaNova Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LivaNova Plc pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LIVN or XTNT?
LivaNova Plc quarterly revenues are $357.8M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. LivaNova Plc's net income of $26.8M is higher than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, LivaNova Plc's price-to-earnings ratio is 38.16x while Xtant Medical Holdings, Inc.'s PE ratio is 59.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LivaNova Plc is 2.59x versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIVNLivaNova Plc2.59x 38.16x $357.8M $26.8M XTNTXtant Medical Holdings, Inc.0.67x 59.83x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 0.06% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 2.97% over the past day.
